Recent studies using CGM (or flash glucose monitoring, FGM) during RF have confirmed an increased time in hyperglycemia and glucose variability, especially in subjects with type 1 diabetes receiving insulin therapy [15,16,17]. This evidence concerns the gene INS and type 1 diabetes mellitus.